Nordea: Novo’s obesity drug is better than Qsymia
Approval of the US company Vivius’ obesity drug Qsymia paves the way for Novo Nordisk to make a grand entrance on the US market with the diabetes/obesity drug Victoza, assesses Nordea.
af LEONORA BECK
According to Nordea, Novo Nordisk has a great success in store. Approval of the obesity drug Qsymia, previously known as Qnexa, will help clear the way for Novo’s diabetes blockbuster Victoza to be used against obesity, the bank believes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
